Founder and CEO

Dr. Meretzki is a visionary leader in regenerative medicine, with over two decades of experience driving innovation in the life sciences. As the founder of Bonus Biogroup, he has spearheaded the development of groundbreaking cell therapy and tissue engineering technologies. Prior to Bonus Biogroup, Dr. Meretzki founded multiple biotech companies, including Pluristem, where he served as CEO and CTO. He holds a Ph.D. in Biotechnology from the Technion - Israel Institute of Technology, in collaboration with the Weizmann Institute of Science. Renowned for his strategic vision and leadership, Dr. Meretzki is dedicated to revolutionizing healthcare through advanced regenerative solutions.

VP of Finance

Mrs. Enbar is an accomplished financial leader with over 15 years of experience driving fiscal strategy and operational excellence. At Bonus Biogroup, she oversees all financial functions, including budgeting, cash flow management, and financial reporting, ensuring compliance with international standards. Previously, as Chief Accountant at Bonus Biogroup, she led financial operations, tax compliance, and internal audits, playing a pivotal role in supporting the company’s strategic goals. Her extensive background includes senior finance roles, where she managed complex global financial structures, consolidated reporting, and treasury operations. Ms. Enbar holds a BA in Accounting and is recognized for her expertise in financial planning and execution, positioning organizations for sustained growth.

Chief Operations Officer.

Dr. Ben-David is an expert in operational management and product development with a focus on advancing regenerative medicine. At Bonus Biogroup, he oversees all operational activities, applying his extensive experience in R&D, regulatory compliance, and manufacturing. He has been instrumental in developing and scaling the company’s innovative cell therapy and tissue engineering products. Dr. Ben-David holds a Ph.D. in Medical Sciences from the Technion - Israel Institute of Technology, with specialization in adult stem cells. His leadership ensures operational excellence and alignment with the company’s mission to deliver cutting-edge treatments.

VP Regulatory & Clinical Affairs

Dr. Kivity brings a wealth of experience in global regulatory and clinical affairs to Bonus Biogroup. With a strong background in pharma, biotech, and medical device companies, she has successfully led submissions to regulatory authorities worldwide. Holding a Ph.D. and MBA degrees from the Technion, the Israeli Institute of Technology, Dr. Kivity ensures that Bonus Biogroup's products meet the highest regulatory standards.

VP Research & Development

Dr. Novak is a leader in cell therapy and tissue engineering with over 15 years of experience translating scientific breakthroughs into life-changing treatments. At Bonus Biogroup, she drives the company’s R&D strategy, leading the development of our advanced regenerative technologies. Holding a Ph.D. from the Technion Faculty of Medicine, Dr. Novak has published extensively in her field and is known for her expertise in stem cell biology. Her visionary leadership ensures that Bonus Biogroup remains at the forefront of scientific innovation, delivering transformative solutions to patients worldwide.

VP Quality Assurance

Dr. Chemouny brings over 20 years of experience in quality assurance, GMP compliance, and pharmaceutical manufacturing to her role at Bonus Biogroup. She oversees all quality management processes, ensuring the company’s products meet rigorous industry and regulatory standards. Before joining Bonus Biogroup, she served as Pharmacist-in-Charge at Taro Pharmaceuticals, where she led quality initiatives for complex pharmaceutical products. Dr. Chemouny’s expertise in quality assurance and operational efficiency supports the company’s commitment to delivering safe and effective treatments.

VP of Innovation & Corporate Development

Dr. Bronshtein is a strategic leader with over 15 years of experience in R&D and business development, specializing in advancing next-generation therapies. At Bonus Biogroup, he is instrumental in identifying and cultivating opportunities that drive the company’s growth and value creation. With a focus on forging impactful collaborations, he establishes strategic partnerships with healthcare providers, industry leaders, and investors. Dr. Bronshtein holds a Ph.D. in Biotechnology Engineering and is recognized for his ability to translate innovative therapies into meaningful solutions for patients and the healthcare providers.

Executive Chairman of the Board

Mr. Rauch brings a wealth of financial expertise to his role, having served as the Chief Economist and Manager of the Economics Department at Leumi PIA, Israel’s largest mutual fund company at the time. He holds an MBA in Finance & Accounting and Computers & Information Systems from Tel Aviv University and a BA in Economics and Business Administration from Bar-Ilan University.

Director

Mr Gil Shapira is the founder and CEO of Propharma Ltd. Founder and partner in Q-il Ltd. Having 30 years experience in managing and implementing projects in the pharmaceutical and biotech industries. Specializing in designing, construction and validation process. Mr Shapira served for 18 years as a CEO of A.D Cleanroom engineering Ltd

External Director

Mr. Shafir is a Partner-CEO in the strategic consulting company Yanai Group and Yanai Peleg & Co., an investment banking company. Mr. Shafir studied Enocmincs at the Hebrew University, Jerusalem.

Director

Mr. Ariel is the CEO of MILOUOT, a company developing, processing, and marketing agricultural produce. Until 2021, he served as the CEO of Biological Industries, a leading supplier to the life science industry that was recently merged into Sartorius AG. Mr. Ariel holds a B.Sc. degree in mechanical engineering.

Director

Ms. Assays is the General Manager of SISMA (www2.sisma.org.il), a non-profit educational organization, and a former member of the National Petroleum Council, Ministry of Energy, Israel. She holds an MBA degree and a BA degree in economics and criminology.

MD

Prof. Rozen is the Head of the Department of Orthopedic Surgery at Ha’Emek Medical Center, Afula. He is the Founder of the Institute for Bone Repair at Rambam Health Care Campus, Haifa, and the Head of the Department of Orthopedic and Traumatology at Zvulun Medical Center, Haifa. Prof. Rozen is a highly recognized researcher in orthopedics with >90 papers published and a particular interest in non-healing fractures making him highly qualified to lead our orthopedic studies.

 DMD

Dr. Tzur is a senior oral and maxillofacial surgeon specializing in implant surgery and craniomaxillofacial rehabilitation and is the former Director of the Oral & Maxillofacial Surgery Unit at Assaf Harofeh Medical Center. He has over 30 years of experience in all aspects of the reconstruction and rehabilitation of hard and soft tissue defects of the oral cavity, jaws, and facial structures. In addition, he is involved in dent-alveolar and orthogenetic surgery, reconstruction of disease and trauma-induced defects, and dental implantology.

MD

Prof. Ullman is the Head of the Department of Plastic and Reconstructive Surgery and Burn Unit at Rambam Health Care Campus and runs the Aesthetic Plastic Surgery Service at the hospital. The main research interests of Prof. Ullman include burn wound healing, fat graft survival, lasers, and complicated traumas. In addition, Prof. Ullmann is a Senior Clinical Lecturer at the Rappaport Faculty of Medicine at the Technion.

Mr. Hoenlein served until 2022 as the Executive Vice Chairman/CEO of the Conference of Presidents of Major American Jewish Organizations, the coordinating body for 53 national Jewish organizations. He received his B.A. from Temple University and completed his doctoral course work at the University of Pennsylvania, where he taught International Relations and was a Middle East specialist at the Foreign Policy Research Institute. He was the Founding Executive Director of the JCRC of Greater New York and the Greater New York Conference on Soviet Jewry. Mr. Hoenlein appears regularly in the media, has three weekly U.S. national radio broadcasts, and has lectured and met leading officials worldwide. He has received numerous awards from the U.S. and foreign governments and institutions, including four Honorary Doctorates.

Mr. Ben Shoshan is the Managing Partner of the Southern Isreal Bridging Fund (SIBF). He has over 15 years of global experience in managing capital, as well as managing and mentoring startup companies. Mr. Ben Shoshan serves as chairman and member of the board of directors of several start-up companies and organizations, both profit and non-profit. Or was also a partner in Sherpa InnoVentures VC fund and is deeply involved in Israel’s venture capital industry.